US2003032634A1PendingUtilityA1

Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance

41
Priority: Jun 1, 2001Filed: Jun 3, 2002Published: Feb 13, 2003
Est. expiryJun 1, 2021(expired)· nominal 20-yr term from priority
Inventors:Jon D. PiganelliKathryn HaskinsSonia C. FloresJames D. CrapoBrian J. DayRonald G. GillRichard E. GammansManisha Patel
A61P 37/06A61K 31/409A61P 39/06A61P 37/00A61P 37/02A61P 9/14A61K 31/555A61P 9/10A61P 3/10
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of preventing or treating diabetes comprising administering to a patient in need of such prevention or treatment an amount of a low molecular weight antioxidant sufficient to effect said prevention or treatment.  
     
     
         2 . The method according to  claim 1  wherein said antioxidant is a porphine or a tetrapyrrole, or pharmaceutically acceptable salt thereof.  
     
     
         3 . The method according to  claim 2  wherein said porphine or tetrapyrrole is bound to a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.  
     
     
         4 . The method according to  claim 3  wherein said metal is manganese.  
     
     
         5 . The method according to  claim 4  wherein said compound is manganese substituted AEOL 10113 or 10150.  
     
     
         6 . The method according to  claim 1  wherein said diabetes results from death of pancreatic islet cells due to autoimmune disease.  
     
     
         7 . The method according to  claim 1  wherein said diabetes results from death of pancreatic islet cells due to free radical induced toxicity.  
     
     
         8 . A method of preventing or treating diabetes-specific microvascular disease comprising 
 administering to a patient in need of such prevention or treatment an amount of an antioxidant sufficient to effect said prevention or treatment, wherein said antioxidant is a porphine or a tetrapyrrole, or pharmaceutically acceptable salt thereof    
     
     
         9 . The method according to  claim 8  wherein said porphine or tetrapyrrole is bound to a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.  
     
     
         10 . The method according to  claim 9  wherein said metal is manganese.  
     
     
         11 . A method of preventing or treating diabetes-accelerated macrovascular atherosclerosis comprising 
 administering to a patient in need of such prevention or treatment an amount of an antioxidant sufficient to effect said prevention or treatment, wherein said antioxidant is a porphine or a tetrapyrrole, or pharmaceutically acceptable salt thereof    
     
     
         12 . The method according to  claim 11  wherein said porphine or tetrapyrrole is bound to a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.  
     
     
         13 . The method according to  claim 12  wherein said metal is manganese.  
     
     
         14 . A method of inducing immune tolerance comprising comprising administering to a patient in need of such induction an amount of a low molecular induction.  
     
     
         15 . The method according to  claim 14  wherein said antioxidant is a porphine or a tetrapyrrole, or pharmaceutically acceptable salt thereof.  
     
     
         16 . The method according to  claim 15  wherein said porphine or tetrapyrrole is bound to a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.  
     
     
         17 . The method according to  claim 16  wherein said metal is manganese.  
     
     
         18 . The method according to  claim 14  wherein said patient is a transplant recipient and said antioxidant renders said patient tolerant to said transplant.  
     
     
         19 . A method of enhancing viability of a cell, tissue or organ comprising contacting said cell, tissue or organ with a low molecular weight antioxidant under conditions such that said viability is enhanced.  
     
     
         20 . The method according to  claim 19  wherein said cell, tissue or organ is transplanted into a host and viability of said transplanted cell, tissue or organ is enhanced.  
     
     
         21 . The method according to  claim 19  wherein said antioxidant is a porphine or tetrapyrrole.  
     
     
         22 . The method according to  claim 21  wherein said porphine or tetrapyrrole is bound to a metal selected from the group consisting of manganese, iron, copper, cobalt or nickel.  
     
     
         23 . The method according to  claim 22  wherein said metal is manganese.  
     
     
         24 . The method according to  claim 19  wherein said cell is a neuronal cell.

Join the waitlist — get patent alerts

Track US2003032634A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.